Gregory Bailey
Known title: DirectorCIK: 0001329505
Gregory Bailey's purchase track record
How the stock did after each of Gregory Bailey's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
11
of 11 since October 25, 2022
Stock higher 6 months later
45%
3 months: 45%
Median 6-month return
-6.9%
3 months: -4.9%
Beat the S&P 500
45%
median -12.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/13/2025 | BHVN | $3.00M | +42.3% | +11.6% | +11.3% |
| 12/17/2024 | SER | $18K | -7.3% | +21.9% | -1.1% |
| 9/24/2024 | BHVN | $221K | -20.6% | -33.7% | +0.8% |
| 9/18/2024 | SER | $95K | +2.0% | -26.3% | +1.0% |
| 8/14/2024 | SER | $200K | -26.9% | -32.8% | +10.9% |
| 5/28/2024 | SER | $146K | -13.3% | -52.5% | +13.5% |
| 5/20/2024 | SER | $46K | -19.1% | -50.0% | +11.0% |
| 5/13/2024 | BHVN | $513K | +9.4% | +55.2% | +14.9% |
| 4/22/2024 | BHVN | $3.00M | -4.9% | +33.9% | +16.8% |
| 10/4/2023 | BHVN | $402K | +75.3% | +128.0% | +22.2% |
| 10/25/2022 | BHVN | $2.10M | +30.0% | -6.9% | +5.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SER | ▼ Sell | Other | 6,666,667 | $15.0M | 6/17/2026 | View on chart |
| SER | ▼ Sell | Other | 1,770,805 | $4.0M | 6/17/2026 | View on chart |
| SER | ▲ Buy | Grant | 59,667 | $116K | 3/31/2026 | View on chart |
| BHVN | ▲ Buy | Open Market | 400,000 | $3.0M | 11/13/2025 | View on chart |
| SER | ▲ Buy | Open Market | 3,866 | $18K | 12/17/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 5,000 | $221K | 9/24/2024 | View on chart |
| SER | ▲ Buy | Open Market | 1,137 | $7K | 9/20/2024 | View on chart |
| SER | ▲ Buy | Open Market | 11,679 | $71K | 9/19/2024 | View on chart |
| SER | ▲ Buy | Open Market | 2,709 | $17K | 9/18/2024 | View on chart |
| SER | ▲ Buy | Open Market | 1,776 | $15K | 8/20/2024 | View on chart |
| SER | ▲ Buy | Open Market | 6,400 | $51K | 8/19/2024 | View on chart |
| SER | ▲ Buy | Open Market | 6,400 | $47K | 8/16/2024 | View on chart |
| SER | ▲ Buy | Open Market | 6,400 | $43K | 8/15/2024 | View on chart |
| SER | ▲ Buy | Open Market | 6,400 | $45K | 8/14/2024 | View on chart |
| SER | ▲ Buy | Open Market | 5,205 | $49K | 5/30/2024 | View on chart |
| SER | ▲ Buy | Open Market | 1,173 | $11K | 5/29/2024 | View on chart |
| SER | ▲ Buy | Open Market | 9,019 | $86K | 5/28/2024 | View on chart |
| SER | ▲ Buy | Open Market | 2,371 | $23K | 5/23/2024 | View on chart |
| SER | ▲ Buy | Open Market | 916 | $9K | 5/21/2024 | View on chart |
| SER | ▲ Buy | Open Market | 1,422 | $14K | 5/21/2024 | View on chart |
| SER | ▲ Buy | Open Market | 100 | $900 | 5/20/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 15,000 | $513K | 5/13/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 25,503 | $999K | 4/24/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 48,780 | $2.0M | 4/22/2024 | View on chart |
| BHVN | ▲ Buy | Open Market | 17,817 | $402K | 10/4/2023 | View on chart |
| BHVN | ▲ Buy | Open Market | 200,000 | $2.1M | 10/25/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 4,119 | $20K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 5,998 | $21K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 9,000 | $28K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 9,000 | $21K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 11,975 | $90K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 1,291,829 | $0 | 10/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Biohaven signs $100M deal with Ono for IgG degraders
Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.
Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.